%0 Journal Article %A Kimberly L Garrison %A Polina German %A Erik Mogalian %A Anita Mathias %T The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection %D 2018 %R 10.1124/dmd.117.079038 %J Drug Metabolism and Disposition %P dmd.117.079038 %X Several safe and highly-effective directly-acting antiviral drugs for chronic hepatitis C virus (HCV) have been developed and greatly increase the number of treatment options available to successfully treat HCV infection. However, as treatment regimens contain at least two drugs (e.g., sofosbuvir with daclatasvir, simeprevir, ledipasvir, or velpatasvir; elbasvir and grazoprevir) and up to five drugs (ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin), the potential for drug-drug interactions (DDI) becomes an important consideration for HCV-infected individuals with comorbidities that require concomitant medications, such as HIV/HCV co-infection or immunosuppression following liver transplantation. This review details the pharmacokinetics and DDI potential of approved DAAs for the treatment of HCV infection. %U https://dmd.aspetjournals.org/content/dmd/early/2018/04/24/dmd.117.079038.full.pdf